SAN FRANCISCO, April 13 /PRNewswire/ -- Cambridge Research & Instrumentation, Inc. (CRi) was presented with Frost & Sullivan's United States Optical Imaging Technologies in Drug Discovery Product Line Strategy Award at the 2009 Excellence in Medical Technologies & Life Sciences award banquet.
The Award recognizes CRi's product development strategy for the in-vitro and in-vivo imaging markets, achieved by creating innovative solutions that address a wide range of unmet needs in life sciences applications. The company's Nuance(TM) and Maestro(TM) multispectral solutions enable researchers and clinicians to quantitatively analyze multiple molecular markers in single cells, in tissues, and in whole organisms, aiding in the understanding the behavior of signaling pathways. Such knowledge is essential for guiding drug development and clinical trials designs.
"By facilitating the analysis of complex biological systems, our solutions are helping our customers build the foundation for personalized medicine," said George Abe, President and CEO of CRi. "It is very rewarding that the technical and strategic approach being taken by the team at CRi is being further recognized with such an award."
CRi recently introduced inForm(TM), an advanced image analysis program that employs machine learning technology to solve challenging image analysis problems. inForm combines a fast, easy to use learn-by-example image segmentation engine with powerful data analysis tools. Unlike conventional systems, the combination of Nuance and inForm can automatically identify and quantify relevant molecular expression patterns and signaling pathway data from clinically relevant cells and tissue regions.
CRi's image analysis software products automate, standardize, and simplify the complex and challenging tasks associated with measuring parameters and signals from associated molecular markers. Reliable data that reflect the distribution of specific molecular markers are essential for obtaining valuable insights into disease mechanisms and can help deliver information that will be required for true personalized medicine to become a reality.
Cambridge Research & Instrumentation, Inc (CRi) is a Boston-based biomedical imaging company providing innovative optical imaging solutions for more than 20 years. CRi's multidisciplinary team is dedicated to providing comprehensive solutions that enable our customers to produce breakthroughs in research and medical care. CRi technology helps extract new disease-specific information from biological and clinical samples in the physiological, morphological, and biochemical context of intact tissues and organisms.
With over 80 patents pending and issued, CRi's award-winning innovations are being utilized around the world in a wide range of settings, ranging from academic researcher to pharmaceutical drug development to clinical medicine. CRi is headquartered in Woburn, Massachusetts, and operates a state-of-the-art manufacturing facility.
For more information, please visit: http://www.cri-inc.com
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 31 offices on six continents. To join our Growth Partnership, please visit http://www.frost.com.
|SOURCE Cambridge Research and Instrumentation, Inc. (CRi)|
Copyright©2009 PR Newswire.
All rights reserved